Tempest Therapeutics Inc
TPST
Company Profile
Business description
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
Contact
2000 Sierra Point Parkway
Suite 400
BrisbaneCA94005
USAT: +1 415 798-8589
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
What to expect from the January Fed meeting
Central bankers are likely to hold interest rates steady, but Wall Street is focused on life after Powell.
stocks
Fortescue costs outpace increasing volume
Higher diesel prices and foreign exchange hit unit cash costs.
stocks
A top global stock to buy after a big change in its forecast
Undervalued by 24%, this wide-moat stock is a buy now.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,268.50 | 94.30 | 1.03% |
| CAC 40 | 8,144.81 | 13.66 | 0.17% |
| DAX 40 | 24,908.24 | 24.84 | -0.10% |
| Dow JONES (US) | 49,412.40 | 313.69 | 0.64% |
| FTSE 100 | 10,207.37 | 58.52 | 0.58% |
| HKSE | 27,126.95 | 361.43 | 1.35% |
| NASDAQ | 23,601.36 | 100.11 | 0.43% |
| Nikkei 225 | 53,333.54 | 448.29 | 0.85% |
| NZX 50 Index | 13,510.88 | 50.14 | 0.37% |
| S&P 500 | 6,950.23 | 34.62 | 0.50% |
| S&P/ASX 200 | 8,941.60 | 96.50 | 1.09% |
| SSE Composite Index | 4,139.90 | 7.30 | 0.18% |